Literature DB >> 17675415

Pharmacogenomics of neuroimmune interactions in human psychiatric disorders.

Julio Licinio1, Claudio Mastronardi, Ma-Li Wong.   

Abstract

There is bidirectional communication between the brain and the immune system. Overproduction of interleukin-1beta (IL-1beta) leads to systemic inflammatory response syndrome (SIRS). The crucial role of IL-1beta in inflammation has been highlighted by studies performed in caspase-1 knockout mice (casp1(-/-)), transgenic mice that lack mature IL-1beta and survive lethal doses of lypopolysaccharide (LPS). We have previously shown that IL-1beta, its receptor IL-1 receptor I (IL-1RI) and caspase-1 are expressed within the brain. Moreover, we documented that peripherally injected LPS triggers a specific spatiotemporal pattern of expression of IL-1beta mRNA within the brain, suggesting that IL-1beta could be a major regulator of the central inflammatory cascade. Therefore, we studied brain transcriptional patterns that occur during LPS-induced SIRS in wild-type and casp1(-/-) mice. We showed patterns of gene expression in wild-type and casp1(-/-) mice that included differential expression of several genes, such as those for cytokines, chemokines, nitric oxide synthase 2 and cyclo-oygenase 2. A key component of the neuroimmune-endocrine axis that is increased by IL-1beta is corticotrophin releasing hormone (CRH). We found increased response to antidepressants in patients homozygous for the GAG haplotype of CRH receptor-1. Our results support the hypotheses that the CRH receptor-1 gene and possibly other genes in stress-inflammatory pathways are involved in the response to antidepressant treatment. Since dysregulation of the neuroimmune-endocrine axis appears to be one of the fundamental biological mechanisms that underlie psychiatric disorders, our findings might contribute to increase the understanding of the molecular pathways that are altered in these diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675415     DOI: 10.1113/expphysiol.2007.038471

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  7 in total

1.  Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report.

Authors:  Bernhard T Baune; Harris Eyre
Journal:  J Med Case Rep       Date:  2010-01-12

2.  Peripheral and central mediators of lipopolysaccharide induced suppression of defensive rage behavior in the cat.

Authors:  S Bhatt; R S Bhatt; S S Zalcman; A Siegel
Journal:  Neuroscience       Date:  2009-07-30       Impact factor: 3.590

Review 3.  Oxidative mechanisms of brain dysfunction during sepsis.

Authors:  Felipe Dal-Pizzol; Cristiane Ritter; Omar J Cassol; Gislaine T Rezin; Fabrícia Petronilho; Alexandra I Zugno; João Quevedo; Emilio L Streck
Journal:  Neurochem Res       Date:  2009-08-14       Impact factor: 3.996

4.  Inflammatory T helper 17 cells promote depression-like behavior in mice.

Authors:  Eléonore Beurel; Laurie E Harrington; Richard S Jope
Journal:  Biol Psychiatry       Date:  2012-11-20       Impact factor: 13.382

5.  The changing roles of neurons in the cortical subplate.

Authors:  Michael J Friedlander; Juan Torres-Reveron
Journal:  Front Neuroanat       Date:  2009-08-07       Impact factor: 3.856

6.  Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression.

Authors:  André Tadić; Dan Rujescu; Matthias J Müller; Ralf Kohnen; Hans H Stassen; Armin Szegedi; Norbert Dahmen
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

7.  Insulin alleviates the inflammatory response and oxidative stress injury in cerebral tissues in septic rats.

Authors:  Qiyi Chen; Wenkui Yu; Jiangliang Shi; Juanhong Shen; Tao Gao; Juanjuan Zhang; Fengchan Xi; Jieshou Li; Ning Li
Journal:  J Inflamm (Lond)       Date:  2014-06-20       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.